EULAR Expands the Role of Patient Research Partners in Rheumatology Research
EULAR has revised its guidance on patient research partner involvement in rheumatology research, replacing the 2011 framework with a broader and more evidence-based update. The 2023 recommendations reflect how patient participation has shifted from a largely aspirational concept into a more structured part of study design, delivery, and interpretation across the rheumatology field.
A task force of 25 members shaped the update, including 13 researchers, 2 health professionals, and 10 patient research partners. The process followed EULAR Standardised Operational Procedures and combined an online task force meeting, a systematic literature review, and an in-person second meeting to refine the final statements. Agreement across the task force was high, ranging from 9.16 to 9.96 on a 0-10 scale, signaling strong consensus around the direction of the revised framework.
New Overarching Principles Define What Meaningful Involvement Looks Like
The update introduced five new overarching principles and revised the conceptual basis for how PRPs fit into rheumatology research. These principles define the PRP role, describe what they contribute, clarify the place of informal caregivers, and emphasize the value of trust and communication in shared research work. The change is more than editorial. It reflects a field that now expects patient involvement to be explicit, purposeful, and integrated rather than added late as a symbolic gesture.
One of the clearest shifts is the recognition that PRPs bring a distinct form of expertise grounded in lived experience of rheumatic disease. In research terms, that expertise can sharpen outcome selection, improve the relevance of study questions, and expose practical burdens that investigators may miss when designing protocols. Caregiver input also appears in the updated principles, acknowledging that some research experiences are shaped not only by the patient’s disease burden but also by the support structures around them.
Trust and communication occupy a central place in the new framework. In collaborative research, these are not soft extras; they are the conditions that determine whether patient involvement is sustained, honest, and useful. When patients and researchers share responsibility for a project, poorly defined roles can quickly weaken the collaboration. Clear expectations, mutual respect, and regular dialogue help prevent PRPs from being treated as decorative advisers rather than active contributors.
The Recommendations Move Deeper Into Study Design, Support, and Training
The updated recommendations cover the phases of research in which PRPs should be involved, the number of PRPs recommended per project, the support they need, how they should be trained, and how their contribution should be acknowledged. Three entirely new recommendations were added. One addresses the benefits of support and guidance for researchers, another calls for regular evaluation of the patient-researcher collaboration, and a third recommends a designated coordinator to facilitate the work.
The addition of a coordinator is especially practical. Research teams often lose momentum when communication is fragmented or when no one is clearly responsible for maintaining patient involvement across meetings, documents, and milestones. A coordinator can help translate between clinical language and lived experience, keep PRPs informed, and make sure their input is incorporated rather than merely recorded. For multicenter or long-running projects, that role can determine whether involvement remains continuous or becomes intermittent and superficial.
The guidance on support and training cuts both ways. PRPs need preparation to contribute effectively, but researchers also need guidance on how to work with PRPs in a way that is respectful and methodologically sound. This matters because patient involvement succeeds when both sides understand the process. Without that shared understanding, studies risk confusing consultation with collaboration, or inviting participation without creating the conditions needed for real influence.
Why These Recommendations Matter for Rheumatology Research
Rheumatology is a specialty in which symptoms, function, fatigue, pain, and treatment burden can diverge sharply from what standard clinical metrics capture. That makes PRP input particularly valuable. A trial can measure inflammation precisely and still fail to capture whether an intervention fits daily life, whether a patient-centered endpoint is meaningful, or whether the visit schedule is realistic for people living with chronic disease. PRPs help close that gap.
The updated EULAR framework also raises the standard for accountability. Regular evaluation of the patient-researcher partnership introduces a feedback loop that can identify early signs of imbalance, confusion, or underuse of patient input. In practical terms, this means patient involvement is no longer treated as a one-time checklist item. It becomes part of the quality control of the research itself.
The evidence base behind the revision is stronger than before, and that is one of the most important features of the update. The older 2011 recommendations helped establish the principle of patient involvement in rheumatology research. The current version goes further by anchoring the recommendations in a more mature body of evidence and by making the operational details more explicit. Researchers now have clearer guidance on when to involve PRPs, how to prepare them, how to support them, and how to recognize their contribution.
A patient partnership that is well structured can alter the trajectory of a study long before results are analyzed. It can improve recruitment materials, shape outcomes that matter to patients, refine consent language, and reduce avoidable burdens in protocol design. Those effects are difficult to quantify in a single endpoint, but they are clinically consequential because they influence whether research answers questions that matter in everyday rheumatology care.
Strong Consensus but Ongoing Dependence on Implementation
The task force agreement scores, ranging from 9.16 to 9.96, show that the recommendations drew broad support from the group assembled to create them. High consensus does not guarantee smooth adoption, however. Research teams will still need to turn the recommendations into routine practice, and implementation will vary across institutions, countries, and study types.
The updated recommendations are designed as a guide for both researchers and PRPs. Their value will depend on whether research groups treat patient involvement as a core methodological feature rather than an optional add-on. In a field where the burden of disease is chronic and the stakes of treatment decisions are often personal and cumulative, a more disciplined approach to partnership may prove just as important as the scientific questions being studied.